Copies of the prospectus concerning this offering may be acquired by contacting Aegis Capital Corp., Prospectus Section, 810 Seventh Avenue, 18th Floor, NY, NY 10019, telephone: 212-813-1010, e-mail:. A registration statement associated with these securities was declared effective by the Securities and Exchange Commission on October 16, 2013 and an abbreviated sign up statement relating to these securities was effective upon filing with the SEC on October 16, 2013. This press release will not constitute an offer to market or a solicitation of an offer to get, nor shall there become any sale of the securities in any constant state or jurisdiction in which such an offer, solicitation or sale will be unlawful ahead of registration or qualification beneath the securities laws of any such state or jurisdiction..The proposed rule will also facilitate clinical study through the allowance of ‘compound authorization’ whereby a researcher can obtain a one consent for a study project which includes both a medical trial and cells banking of specimens, than obtaining separate consent for every activity rather. ACRO urges HHS to consider additional changes to the HIPAA guidelines that would streamline the study process, such as allowing researchers to get individual authorization for ‘potential and unspecified’ research, which is currently prohibited. This proposed guideline implements provisions of The Health Information Technology for Financial and Clinical Health Act approved in February 2009, which greatly expanded the privacy provisions of the Health Insurance Portability and Accountability Take action of 1996 ..